Cohance Pashamylaram Plant Gets USFDA VAI Classification
On 7 November 2026, Cohance Lifesciences said the USFDA classified its Pashamylaram, Hyderabad plant as VAI, formally closing the July-August inspection.
On 7 November 2026, Cohance Lifesciences said the USFDA classified its Pashamylaram, Hyderabad plant as VAI, formally closing the July-August inspection.
Alkem Laboratories’ Mandva API facility cleared a five-day USFDA inspection (26–30 October 2026) with no Form 483 observations, a cleaner result than the site’s 2023 audit.
The USFDA issued a Form 483 with 11 observations to Granules India’s Gagillapur finished dosage plant, its first inspection since the February 2025 Warning Letter; the company says supply is unaffected.
The USFDA has classified Dr. Reddy’s FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, as Voluntary Action Indicated and closed the inspection, three months after a pre-approval and GMP audit ended with a Form 483 carrying three observations.